01—Abstract
Summary
Summary of the 10-K filed February 16, 2021. Cited figures are marked; the original filing is the authoritative source.
Zoetis Inc. reported robust performance for the fiscal year ended December 31, 2020, with total revenue reaching $6.68 billiona, a 7% increase year-over-year.
This growth was primarily driven by strong performance in companion animal products, which saw a 16% increase in revenue, and a 3% operational revenue growth in international markets. The company's financial health remained solid, supported by healthy operating cash flows. Zoetis continues to invest significantly in research and development, allocating $463 millionb in 2020 to drive innovation and expand its product lifecycle.
Key product lines like Apoquel and the Simparica franchise demonstrated strong revenue contribution, underscoring the company's focus on high-demand therapeutic areas. Despite facing economic uncertainties and the ongoing impact of COVID-19, Zoetis maintained its market leadership position in the animal health industry.
02—Key points
Key Highlights
- Total revenue increased by 7% to $6.68 billion in 2020, driven by strong companion animal product sales (+16%) and international operational growth (+7%).
- The company invested $463 million in Research and Development (R&D) to fuel innovation and product lifecycle expansion.
- Top products like Apoquel and the Simparica franchise, along with other key products (Revolution, Draxxin, ceftiofur line), collectively contributed 31% of total revenue, demonstrating product concentration.
- Zoetis reported solid net income of $1.64 billion, a 9% increase year-over-year, and maintained effective cost management with cost of sales as a percentage of revenue decreasing to 31%.
- The U.S. segment revenue grew by 11% to $3.56 billion, with companion animal products being the primary driver, while the international segment saw a 2% revenue increase, despite a 5% negative impact from foreign exchange.
- The company maintained a strong liquidity position with $3.60 billion in cash and cash equivalents as of December 31, 2020.
- Zoetis continued its strategic acquisitions, including Fish Vet Group, Virtual Recall, Performance Livestock Analytics, and Ethos Diagnostic Science, to expand its offerings in diagnostics, data analytics, and precision livestock farming.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 16, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $6.67B$6.26B | +6.6% |
| Cost of Revenue | $2.06B$1.99B | +3.3% |
| Gross Profit | $4.62B$4.27B | +8.2% |
| SG&A Expenses | $1.73B$1.64B | +5.4% |
| Interest Expense | $231.00M$223.00M | +3.6% |
| Net Income | $1.64B$1.50B | +9.1% |
| EPS (Basic) | $3.44$3.14 | +9.6% |
| EPS (Diluted) | $3.42$3.11 | +10.0% |
| Shares Outstanding (Basic) | 475.50M478.13M | −0.5% |
| Shares Outstanding (Diluted) | 478.57M481.79M | −0.7% |
05—Questions
Frequently Asked Questions
What was Zoetis' overall revenue performance in 2020?
Zoetis reported total revenue of $6.68 billion for the fiscal year ended December 31, 2020, representing a 7% increase compared to the previous year. This growth was driven by strong performance across its product portfolio, particularly in companion animal products.
How did Zoetis' R&D investment impact its strategy?
Zoetis invested $463 million in Research and Development (R&D) in 2020, a slight increase from the prior year. This investment reflects the company's commitment to innovation, focusing on new product development and product lifecycle innovations to maintain its competitive edge and address evolving customer needs.
What are the key growth drivers for Zoetis' companion animal and livestock segments?
For companion animals, growth is driven by increasing pet ownership, longer lifespans of pets, greater access to veterinary care, and advances in medical treatments. For livestock, growth is supported by global population increase, rising living standards, and the growing demand for safe and high-quality animal protein.
How did the COVID-19 pandemic affect Zoetis' operations and financial results?
While Zoetis was designated as an essential business and maintained operations, the COVID-19 pandemic did impact its business through disruptions to its customers' operations, supply chains, and reduced demand in certain areas. However, the company managed to navigate these challenges, reporting revenue growth and maintaining solid financial performance.
06—Continue